Immunization against potential biological warfare agents

Clinical Infectious Diseases

Volumn 30, Issue 6, 2000, Pages 843-850

  Cieslak, Theodore J ^a   Christopher, George W ^a   Kortepeter, Mark G ^a   Rowe, John R ^a   Pavlin, Julie A ^a   Culpepper, Randall C ^a   Eitzen, Edward M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

BACTERIAL INFECTION; BIOLOGICAL WARFARE; HEALTH CARE PERSONNEL; HUMAN; IMMUNIZATION; LAW ENFORCEMENT; MILITARY PHENOMENA; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; REVIEW; VACCINATION;

BACTERIAL INFECTIONS; BACTERIAL VACCINES; BIOLOGICAL WARFARE; HUMANS; IMMUNIZATION; VIRAL VACCINES; VIRUS DISEASES;

EID: 0034465842     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313812     Document Type: Review

References (73)

1. Terrorism's next wave
2. Weapons of mass destruction
3. Confronting a biological armageddon: Experts tackle prospect of bioterrorism
4. The specter of biological weapons
5. Biological terrorism
6. The looming threat of bioterrorism
7. Japanese cult had network of front companies
8. Anthrax vaccines: Past, present and future
9. Human live anthrax vaccine in the former USSR
10. Purification of factor I and recognition of a third factor of the anthrax toxin
11. The three factors of anthrax toxin: Their immunogenicity and lack of demonstrable enzymic activity
12. The Sverdlovsk anthrax outbreak of 1979
13. Recent advances in the development of an improved human anthrax vaccine
14. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis
15. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen
16. Experimental anthrax vaccines: Efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs
17. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen
18. Bioterrorism alleging use of anthrax and interim guidelines for management United States
19. DeMussis and the great plague of 1348
20. Japanese biological warfare research on humans: A case study of microbiology and ethics
21. Remarks on the plague prophylactic fluid
22. Plague immunization. I. Past and present trends
23. Effectiveness of live or killed plague vaccines in man
24. Some observations on the current plague outbreak in the Republic of Vietnam
25. Plague immunization V. Indirect evidence for the efficacy of plague vaccine
26. Prevention of plague: Recommendations of the advisory committee on immunization practices
27. Measuring the efficacy of vaccination in affording protection against plague
28. Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine
29. Clinical and serological responses to plague vaccine
30. Immunity in plague: Protection of the vervet (Cercopithecus aethiops) against pneumonic plague by the oral administration of live attenuated Yersinia pestis
31. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis
32. A subunit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague
33. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine
34. An overview of human brucellosis
35. Immunization with viable Brucella organisms
36. Experimental study of Brucella chemical vaccine
37. La vacination humaine contre les brucelloses
38. Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models
39. The tularemia vaccine
40. Cell-mediated and humoral immune response induced by scarification vaccination of human volunteers with a new lot of the live vaccine strain of Francisella tularensis
41. Vaccination against Q fever
42. Prevention of Coxiella burnetii infection: Vaccines and guidelines for those at risk
43. Q fever down the drain
44. Vaccine prophylaxis of abattoirassociated Q fever
45. Comparative efficacy of a Coxiella burnetii chloroform: Methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol
46. Safety and immunogenicity in human volunteers of a chloroform: Methanol residue vaccine for Q-fever
47. Centers for Disease Control Vaccinia (smallpox) vaccine recommendations of the immunization practices advisory committee (ACIP)
48. Immunologic responses to vaccinia vaccines administered by different parenteral routes
49. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea pig heart cells
50. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine
51. Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84)
52. Protective efficacies of live-attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters
53. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1
54. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro an immunization against heterologous pathogens in vivo
55. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates
56. Gene therapy: Promises, pitfalls, and prognosis
57. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli
58. Staphylococcal enterotoxin B and related pyrogenic toxins
59. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres
60. Engineered bacterial superantigen vaccines
61. Protection of mice from inhaled ricin by vaccination with formalinized ricin toxoid
62. Dependence of ricin toxoid vaccine efficacy on the structure of poly(lactide-co-glycolide) microparticle carriers